bullish
CHMP Meeting Update: 4 New Medicines Recommended For Approval, Reinstates Previous Leqembi Decision
343 Views03 Mar 2025 00:30
EMA’s CHMP recommended three new and one generic medicines for approval at its February 2025 meeting. The committee concluded that its positive opinion for Leqembi does not need to be updated.
What is covered in the Full Insight:
- CHMP February 2025 Meeting Outcomes
- New Medicines Recommended for Approval
- Extensions of Therapeutic Indications
- Re-examination Outcomes and Withdrawals
- Other Regulatory Updates
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »- Merck’s $25 Billion Lifeline Is About to Expire — Here’s the Bold Plan to Replace It!
- Merck & Co. Inc.: Expanding Oncology Portfolio through KEYTRUDA Developments & Partnership Collaborations To Shape the Future! - Major Drivers
- Merck & Co: Blockbuster Drugs - [Business Breakdowns, EP.189]
- Merck & Co.: Expanding Market for GARDASIL
- Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna & Other Major Drivers
Trending Collections
More »Trending Insights
More »- Gold Road Enters Scheme With Gold Fields
- Quiddity Leaderboard CSI 300/500 Jun25: Momentum Turning Positive for This Major Rebal Trade
- Merger Arb Mondays (05 May) - Makino, Shibaura, 7&I, Dickson, Meilan, Soundwill, Smartpay, Pointsbet
- Global Reshuffling: Whether India Will Win from China+1?
- Crude Awakening: Shell’s Possible Bid to Refine BP’s Future
Discussions
(Paid Plans Only)
- CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval27 Apr 2025
- CHMP Meeting Update: Five New Medicines Recommended for Approval, Rejects Kisunla Application01 Apr 2025
- CHMP Meeting Update: 4 New Medicines Recommended For Approval, Reinstates Previous Leqembi Decision03 Mar 2025
- CHMP Meeting Update: Eight New Medicines Recommended For Approval03 Feb 2025
x